Company Future Sales Volume: Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics Inc - graphic logo of issuer YMAB

Y-mAbs Therapeutics (YMAB) is actively scaling its commercial footprint by expanding its pipeline of pediatric oncology drugs. Insurance coverage for critical pathologies ensures business stability, while AI enhances the efficiency of antibody development. The company's projected sales levels reflect expected cash flow dynamics, where the current parameter value is 0.09, confirming the potential for growth in the issuer's market value.

Company Future Sales Volume: Y-mAbs Corp (YMAB) for 07/04/2022 - 09/27/2025

Analytical breakdowns for Y-mAbs Corp (YMAB)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Basic company analysis:Y-mAbs Therapeutics, Inc. YMAB
Brand item of YmAbs

To assess the operational resilience of assets, the investor analyzes the alignment of market expectations with actual commercial data, as expressed by the value of 0.09. This projected sales revenue allows for tracking the scaling efficiency of the targeted antibody portfolio within US hospitals and through distributors, identifying deviations from the investment mandate prior to the publication of financial statements to protect capital from drawdowns for Y-mAbs Therapeutics (YMAB).

Direct competitors

Projected Sales Volume ONC|HALO (Halozyme) - Company Future Revenue|Projected Sales Volume RVMD (revmed.com)|Company Future Sales Ascentage (AAPG)|CGON: Company Future Sales Volume|Company Expected Sales Volume UroGen Pharma Ltd.|BCAX: Projected Sales Volume|PSNL - Company Future Sales|ERAS (Erasca Oncology) - Projected Sales Volume|Projected Sales Volume Delcath Systems, Inc.|Projected Sales Volume AURA|Company Projected Revenue CADL (Candel)|Accuray, Inc. - Company Future Sales Volume|SELLAS Life Sciences Group Inc. - Company Projected Revenue|ACTU: Company Future Sales Volume|Company Expected Sales Volume Citius Oncology Inc|HURA: Projected Sales Volume|TARA: Company Projected Revenue Volume|FATE (fatetherapeutics.com) - Projected Sales Volume|Company Future Sales Volume Aadi Bioscience Inc (WHWK)|Projected Sales Volume TCRX|CSBR - Company Expected Sales Volume|Projected Sales Volume XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Company Expected Sales Volume|OSTX: Company Future Sales Volume|Company Future Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Projected Revenue|ANL: Company Projected Revenue Volume|VERU (Veru Corporation) - Projected Sales Volume|Company Expected Sales Volume Tempest Therapeutics, Inc. TPST|Projected Sales Volume XLO|Renovaro - Company Revenue Forecast|Company Projected Revenue Mural Bio MURA|KAPA: Company Revenue Forecast|OnKure Therapeutics - Projected Sales Volume|Company Future Sales w2.cytomed.sg GDTC|CRIS: Projected Sales Volume|Company Future Sales Volume Apollomics Inc.|THAR (Tharimmune Corporation) - Projected Sales Volume|Projected Sales Volume Advanced Biomed Inc|Projected Sales Volume GNPX|Company Future Sales Volume Calidi Biotherapeutics Inc. CLDI|Company Projected Revenue Sunshine Biopharma Inc. SBFM|Company Future Sales Xenetic Biosciences (XBIO)|SLRX - Company Projected Revenue|Company Expected Sales Volume Kitov Pharma|AON (AONC) - Company Projected Revenue|Company Future Sales Volume BeiGene|Company Projected Revenue checkpointtx.com|Company Revenue Forecast ELEV (Elevation Oncology)|Projected Sales Volume ICAD|Ikena Oncology - Company Revenue Forecast|Company Projected Revenue Notable Labs, Ltd. NTBL|VIRX: Company Revenue Forecast|MOR - Company Projected Revenue|NAYA Bio (NAYA) - Company Future Sales Volume|AAPGV: Projected Sales Volume